Indeed, CD34+ CML cells treated with the BMI1 inhibitor PTC-209, failed to achieve clonogenicity [92] leaving hope for a possible targeting of LSCs. This evidence concerns the gene BMI1 and chronic myelogenous leukemia, BCR-ABL1 positive.